KMT2D and breast cancer: A recent study indicated that treatment with the PI3Kα inhibitor induced an adaptive enhanced ERα signaling by activating KMT2D, a H3K4 methyltransferase in ER+ breast cancer cells with PIK3CA mutation [41], indicating therapeutic resistance to PI3Kα inhibitor.